mifepristone has been researched along with Androgen-Independent Prostatic Cancer in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cen, S; Cui, X; He, Y; Huang, C; Li, X; Liu, M; Wu, M; Xie, Y; Zhang, R; Zhou, J | 1 |
| Anderson, A; Chu, YL; Heath, EI; Karrison, T; Martinez, E; Schonhoft, J; Serritella, AV; Shevrin, D; Stadler, WM; Szmulewitz, RZ; Wade, JL | 1 |
| Kucuk, O; Li, X; Mamouni, K; Wu, D; Yang, Y | 1 |
1 trial(s) available for mifepristone and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Benzamides; Humans; Male; Mifepristone; Nitriles; Phenylthiohydantoin; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Glucocorticoid | 2022 |
2 other study(ies) available for mifepristone and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Rational drug design for androgen receptor and glucocorticoids receptor dual antagonist.
Topics: Androgen Receptor Antagonists; Cell Proliferation; Drug Design; Humans; Male; Molecular Docking Simulation; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Protein Conformation; Receptors, Androgen; Receptors, Glucocorticoid; RNA, Messenger; Transcription, Genetic; User-Computer Interface | 2019 |
Mifepristone Has Limited Activity to Enhance the
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Bone Neoplasms; Cell Proliferation; Docetaxel; Hormone Antagonists; Humans; Male; Mice; Mifepristone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |